BioSpace News Archive

Servier, a global independent pharmaceutical group, and Owkin, a French American biotech focused on applying artificial intelligence (AI) to drug discovery,

Alcami Corporation (“Alcami”) today welcomed the recent announcement by Nectero Medical that they have received clearance from the U.S. Food and Drug Administration of their IND application to initiate Phase II/III trial of the Nectero Endovascular Aneurysm Stabilization Treatment (EAST®) System for the treatment of small- to-mid-sized abdominal aortic aneurysms (AAA).

Gynesonics®, Inc. a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, is pleased to announce that its Sonata® Procedure has been used to treat over 1,000 women in the United States and approximately 6,500 women globally.

Diamond Therapeutics Inc. (“Diamond”), a clinical-stage drug development company focused on non-hallucinogenic, psychedelic-based therapies for use in the treatment of mental health, today announced the enrollment of the first patient in an FDA-approved clinical trial conducted at the University of Alabama at Birmingham (UAB).

VySpine, a spine innovation leader using differentiated materials and designs, announced today that it has received a trio of U.S. Food and Drug Administration (FDA) clearances for its products, providing increased diversity to the company’s portfolio.

Predicine, a pioneer in the liquid biopsy, announce its participation in the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

Cingulate Inc. announced that it will be hosting a key opinion leader event on the morning of October 23, 2023, at the Union League Club in New York City.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Market Authorization for the expanded use of PrTRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosis (CF) ages 2 to 5 years who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

New research from Shady Grove Fertility (SGF), a US Fertility practice, assures fertility patients who have undergone a saline-infused sonogram (SIS) that they can proceed with intrauterine insemination (IUI) in the same cycle and expect comparable pregnancy rates as if they had waited for another cycle.

The Alzheimer’s Drug Discovery Foundation will be moderating a session, “Emerging Solutions: Novel Approaches to Treating Alzheimer’s Disease,” at the 2023 Clinical Trials on Alzheimer’s Disease conference, which will be held October 24th through 27th at Boston Park Plaza in Boston, Massachusetts.